HST Global Announces Details of Protocol Licensing for Health Matters International
May 04 2010 - 8:30AM
Business Wire
HST Global, Inc. (OTCBB: HSTC) today announced that it has
formalized the licensing details for Health Matters
International.
As previously announced, HST Global Inc. (HST) has partnered
with Health Matters International (HMI), a Canadian Company that
has vast international knowledge in the Healthcare Industry.
Through this association, HMI identified Panama and Costa Rica as
potential countries for the development of HST’s Clinical Treatment
Facilities which features the company’s “FIT” protocol.
HMI focuses on providing a solution to the rising cost of
prescription medications and other health care related matters.
They pride themselves on ensuring safe, high quality and low cost
prescription medications through their Canadian and International
Pharmacies. Headquartered in Calgary, Alberta with pharmacies in
New Zealand, Italy, India, USA and Canada they employ a safe, high
quality and low cost methodology for delivery of prescription
medication.
HMI will be funding the initial licensing fee. HMI’s licensing
fee will be $250,000. This license fee will permit HMI to provide
the “FIT” protocol within Panama and Costa Rica. The fee
incorporates training, initial products and onsite development for
each respective clinical team. In addition, HMI will pay a royalty
on each individual application of the “FIT” protocol administered
within each clinic. The clinics will also be purchasing a regime of
post-therapy medications also provided by HST under the same
royalty agreement.
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and
Wellness company that is developing and or acquiring a network of
Wellness Centers worldwide that are primarily focused on the
immunotherapy and alternative treatment of late stage cancer. In
addition, the company intends to acquire innovative products for
the treatment of late stage cancer. In this regard, the company
primarily focuses on immunotherapy and alternative product
candidates that are undergoing or have already completed
significant clinical testing for the treatment of late stage
cancer.
HST Global, Inc. wishes to inform readers that forward-looking
statements in this release are made pursuant to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Readers are cautioned that such forward looking statements involve
risks and uncertainties including, without limitation, unforeseen
changes in the course of research and development activities and in
clinical trials by others; possible acquisitions of other
technologies, assets or businesses; possible actions by customers,
suppliers, competitors, regulatory authorities; and other risks
detailed from time to time in the Company's periodic reports filed
with the Securities and Exchange Commission.
HST Global (PK) (USOTC:HSTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
HST Global (PK) (USOTC:HSTC)
Historical Stock Chart
From Jul 2023 to Jul 2024
